Please login to the form below

Not currently logged in
Email:
Password:

Pfizer enters $210m+ nanomedicines deal with Bind

Will use Accurin technology to develop highly selective medicines

Bind Accurin nanotechnology

Pfizer is to research nanomedicines for several diseases in a partnership with Bind Therapeutics that could be $210m per product developed.

The deal focuses on Bind's targeted therapeutics called Accurins, which the company says can outperform conventional drugs by selectively seeking out diseased tissues and cells.

This means there is a higher drug concentration at the necessary site of action, meaning a more effective and safe medicine.

No specific therapy areas were mention by the company, although Bind has said Accurins have the potential to improve patient outcomes in oncology, inflammatory diseases and cardiovascular disorders.

Under the terms of the agreement, both companies will work on preclinical research, while Pfizer will then have the exclusive option to pursue development and commercialisation of selected Accurins.

In return, Bind could receive upfront and development milestone payments totalling $50m and regulatory and sales milestone payments of about $160m for each Accurin commercialised. There will also be tiered royalties on potential future sales.

This is the second major deal Bind has made with a large pharma company this year following a $226m+ deal with Amgen in January.

As noted in the PMLiVE article, Future imperfect: How breakthrough technology can support healthcare, nanotechnology is predicted to have a large impact on healthcare in the coming years, with nanomaterials already being used in the production processes of other industries.

This includes products such as plasma screens, car paints and batteries for mobile phones.

“This is our second collaboration focused on developing novel Accurins based on Bind's platform for targeted and programmable therapeutics and further validates the importance of targeted nanomedicines as a strategic technology for the pharmaceutical industry,” said Scott Minick, president and CEO of Bind.

8th April 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics